BIOTECHNOLOGY and BIOPHARMACEUTICS



Assoc. Prof. Fadime KIRAN




04

- Biopharmaceuticals: From Idea to Industry



DRUG DEVELOPMENT



Drug Development Process



Step 1: Discovery & Development

Phase	Target Discovery	Target Validation	Lead Generation & Refinement	Preclinical Development
Goal	Find All Targets	Eliminate Wrong Targets	Generate Molecules	Eliminate Advance Molecules Molecules

Step 2: Preclinical Research




Researchers determine the following about the drug:


- ✓ Absorption, distribution, metabolization, and excretion information
- ✓ Potential benefits and mechanisms of action
- ✓ Best dosage, and administration route
- ✓ Effects on gender, race, or ethnicity groups
- ✓Interaction with other treatments

✓ Side effects/adverse events

✓ Effectiveness compared to similar drugs



Step 3: Clinical Development



Step 4: FDA Review



- **≻Toxicity**
- **≻**Efficacy
- •
- **▶PK Properties or Bioavailability**
- >Inadequate Drug Performance

Step 5: Post-market Monitoring


EARLY DRUG PRECLINICAL CLINICAL POST-MARKET **FDA REVIEW DISCOVERY** STUDIES DEVELOPMENT MONITORING Target Identification & In Vivo, In Vitro & Ex Phase I – Healthy NDA / ANDA / BLA FDA Adverse Event Validation Vivo Assays Volunteer Study **Application** Reporting System (FAERS) ADME Phase II and Phase III – FDA Approval Hit Discovery Studies in Patient Proof of Concept Assay Development & Drug Registration **Population** Screening Drug Delivery Dose Escalation, Single High Throughput Ascending & Multiple Formulation Screening **Optimization & Dose Studies** Hit to Lead **Bioavailability** Safety & Efficacy Lead Optimization Dose Range Finding Pharmacokinetic IND-enabling Studies **Analysis Bioanalytical Method** IND Application Development and Validation

Brought to you by MISFIT www.misfitwearables.com/references

DRUG DISCOVERY

M

building UP to a let DOWN



After all that effort, only 1 in
4 of us take it properly!



3 in 4 of us are non-adherant in one or more ways

Non-adhering patients contribute to an estimated \$300 Billion in additional healthcare costs!



